A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 3, 2015, Pages 295-306

  Jung, Chang Hee ^a   Park, Cheol Young ^b   Ahn, Kyu Joeng ^c   Kim, Nan Hee ^d   Jang, Hak Chul ^e   Lee, Moon Kyu ^f   Park, Joong Yeol ^a   Chung, Choon Hee ^g   Min, Kyung Wan ^h   Sung, Yeon Ah ⁱ   Park, Jeong Hyun ^j   Kim, Sung Jin ^k   Lee, Hyo Jung ^k   Park, Sung Woo ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

^d Korea University   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Samsung Medical Center   (South Korea)

^g Wonju Severance Christian Hospital   (South Korea)

^h Eulji General Hospital   (South Korea)

ⁱ Ewha Womans University   (South Korea)

^j Inje University College of Medicine   (South Korea)

^k Clinical Research Team Daewoong Pharmaceutical   (South Korea)

more..

Author keywords

Dose finding study; DPP IV inhibitor; Monotherapy; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; DA 1229; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; UNCLASSIFIED DRUG; 4-(3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL)-3-(TERT-BUTOXYMETHYL)PIPERAZIN-2-ONE; GLYCOSYLATED HEMOGLOBIN; PIPERAZINE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES CONTROL; DIET; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMORRHOID; HUMAN; HYPERGLYCEMIA; INSOMNIA; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; ORAL GLUCOSE TOLERANCE TEST; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; ROTATOR CUFF RUPTURE; SINGLE BLIND PROCEDURE; SLEEP DISORDER; THORAX PAIN; URTICARIA; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; FOLLOW UP; GLYCEMIC INDEX; ORAL DRUG ADMINISTRATION; PROGNOSIS;

ADMINISTRATION, ORAL; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIET; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS;

EID: 84924287356     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2613     Document Type: Article

References (26)

1. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
2. Esposito K, Bellastella G, Giugliano D. When metformin fails in type 2 diabetes mellitus. Arch Intern Med 2011; 171: 365-366.
3. Yang SJ, Min KW, Gupta SK, et al. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 410-416.
4. Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs 2011; 71: 611-624.
5. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010; 70: 2089-2112.
6. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 2051-2072.
7. Neumiller JJ, Campbell RK. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm 2010; 67: 1515-1525.
8. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 489-512.
9. Pei Z. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr Opin Drug Discov Devel 2008; 11: 512-532.
10. Capuano A, Sportiello L, Maiorino MI, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. Drug Des Devel Ther 2013; 7: 989-1001.
11. Kim MK, Chae YN, Kim HD, et al. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci 2012; 90: 21-29.
12. Kim TE, Lim KS, Park MK, et al. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. Clin Ther 2012; 34: 1986-1998.
13. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes 2010; 1: 36-47.
14. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007; 23: 1329-1339.
15. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61: 171-180.
16. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692-698.
17. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.
18. Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010; 33: 1859-1864.
19. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 741-750.
20. Reimer MK, Holst JJ, Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002; 146: 717-727.
21. Squier W, Jansen A. Abnormal development of the human cerebral cortex. J Anat 2010; 217: 312-323.
22. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
23. Rhee EJ, Lee WY, Yoon KH, et al. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 1113-1119.
24. Kim KJ, Lee BW. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab J 2012; 36: 98-107.
25. Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2008; 2: 1094-1100.
26. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.